Clinical Trial

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-24; most recent amendment 2026-02-12.
Status change: Recruiting → Completed 2026-02-12
Status change: Not Yet Recruiting → Recruiting 2025-08-25
Trial Details
NCT Number NCT07050368
Lead Sponsor MycoMedica Life Sciences PBC
Conditions Healthy Volunteer
Enrollment 20 participants
Start Date 2025-07-28
Primary Completion 2026-01-13 (estimated)
Study Completion 2026-01-13 (estimated)
Updated on ClinicalTrials.gov 2026-02-13